Corporate Updates 759

Alvogen gets US FDA nod to market antiviral drug

US FDA has given a green signal to the marketing partner of Natco Pharma, Alvogen to market oseltamivir phosphate powder —an antiviral medication used for the treatment of influenza virus types A and B in the body — for oral suspension in the United States.

Natco Pharma said: “Alvogen has received final approval and is the first to market generic equivalent to oseltamivir phosphate, 6 mg/ml powder”.

The Chairman and CEO of Alvogen Robert Wessman, said: “The approval and launch of Alvogen’s oseltamivir phosphate powder for oral suspension is great news for the US patients, who will have access to a more affordable alternative.”  

According to IMS Midas data, the annual sales for Oseltamivir suspension amount to the US $312 million in the U.S. market.

Currently, 75 products of Alvogen are in development and pending for FDA approvals for the U.S. market.

Most Popular

 

 


 

 

 

 

 

Get Heard Portal

 

eHealth Event Report

 

 

To Top